39 percent of blood cancer patients were seen to have lower levels of antibody recovery in the trial. Caroline Donoghue, Senior Scientific Knowledge and Communications Officer at blood cancer research organisation, Myeloma UK, told the Daily Express: “Data has consistently shown that some myeloma patients, especially those on treatment, do not respond as well to COVID-19 vaccines, with some patients producing markedly lower levels of antibodies or even no antibodies in response to the vaccines.
“Many myeloma patients are still living in limbo as a result, not knowing whether the vaccines are helping to protect them against COVID-19. To have this data on the immune response to the first and second dose of the vaccine in immunocompromised is fantastic.
“It clearly shows there is an increase in immune response from first dose to second dose in immunocompromised patients. This suggests that patients could benefit from a third dose and booster and why the data played a big role in the JCVI’s decision to recommend a third primary dose of the vaccine for this group.”
A new study, named Octave Duo, has been launched to find if a third booster jab makes a difference for those who vaccines are less effective for.